Every 8-K that Edesa Biotech, Inc. (EDSA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow EDSA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EDSA filings page.
Edesa Biotech, Inc. (EDSA) entered into an underwriting agreement with Guggenheim Securities for a primary underwritten, registered offering of (i) 3,870,500 common shares with accompanying common share warrants and (ii) pre-funded warrants to purchase up to 675,000 common shares with accompanying common share warrants. Each common share plus warrant unit is priced at $5.50, and each pre-funded warrant plus warrant unit at $5.4999.
The common share warrants have a $7.50 exercise price and expire on the earlier of 18 months from issuance or 30 days after Edesa publicly announces Phase 2 vitiligo topline data for EB06. Gross proceeds are expected to be about $25.0 million and net proceeds about $23.1 million, with a 30‑day underwriters’ option for up to 681,825 additional shares and warrants. Edesa plans to use proceeds for general corporate purposes, including working capital, capital expenditures, and research and development and manufacturing expenses.
Edesa Biotech, Inc. reported fiscal third-quarter 2026 results and business updates. The company completed preparations for a Phase 2 clinical study of EB06 for moderate-to-severe vitiligo and began activating investigational sites after quarter-end, with initial recruitment expected in Canada, followed by additional jurisdictions subject to regulatory approvals.
In its respiratory program, exploratory analyses in ARDS patients with concurrent acute kidney injury associated paridiprubart plus standard of care with mortality reductions and improvements in the kidney-specific MAKE30 composite endpoint, and Edesa is evaluating regulatory pathways and strategic options. Financially, total operating expenses for the quarter rose to $5.5 million from $1.9 million a year earlier, driven mainly by higher R&D spending on EB06 and increased general and administrative costs. Net loss for the quarter widened to $5.4 million, or $0.60 per share, from $1.7 million, or $0.25 per share. For the nine months ended June 30, 2026, net loss was $11.9 million versus $5.0 million in the prior-year period. At June 30, 2026, Edesa held $10.3 million in cash and cash equivalents and reported working capital of $6.9 million.
Edesa Biotech, Inc. entered into a securities purchase agreement for a private placement of approximately $3.5 million of common shares. The company plans to sell 729,241 shares in a PIPE financing, at $4.69 per share for investors and $5.21 per share for its Chief Executive Officer.
The closing is expected on June 15, 2026, subject to customary conditions. Edesa expects to use the net proceeds to advance its vitiligo program, its drug candidate paridiprubart, and for working capital and general corporate purposes. A Registration Rights Agreement requires Edesa to file one or more resale registration statements with the SEC within 45 days of closing.
Edesa Biotech reported new exploratory subgroup data for paridiprubart, its anti-TLR4 antibody, in critically ill patients with acute kidney injury and respiratory distress. Analyses pooling Phase 2 and Phase 3 studies created a 101-patient AKI subgroup from a broader 278-patient population with acute respiratory distress syndrome.
Paridiprubart plus standard of care was associated with adjusted 28-day mortality of 33% versus 49% for placebo, a 32% relative reduction in risk of death, and reduced major adverse kidney events (MAKE30) to 41% versus 53%, with nominal p<0.005 for both endpoints. Safety in the AKI subgroup remained consistent with more than 400 patients treated to date.
The company emphasizes that these AKI findings are exploratory, were not prespecified, use multivariate logistic regression, and are intended to generate hypotheses. Confirmatory studies would be required to establish efficacy in AKI, though the results support ongoing ARDS development and potential future AKI-focused trials.
Edesa Biotech, Inc. reported results of its 2026 Annual General and Special Meeting of Shareholders. Shareholders approved an amendment to the 2019 Equity Incentive Compensation Plan to increase shares available for issuance by 750,000 and remove the annual per-participant option grant limit.
All seven director nominees were elected to serve until the 2027 annual meeting, with support of roughly 2.67–2.71 million votes for each and 2,147,101 broker non-votes. Shareholders also approved, on an advisory basis, executive compensation and ratified MNP LLP as auditors for the fiscal year ending September 30, 2026.
The company reported that 4,901,921 common shares, or about 55% of shares entitled to vote, were represented in person or by proxy at the meeting.
Edesa Biotech disclosed that Chief Executive Officer Dr. Pardeep Nijhawan has elected to receive a much larger portion of his compensation in stock-based awards rather than cash. Under his Amended and Restated Employment Agreement, the Board approved that 90% of his monthly base salary will now be paid in the form of fully vested restricted share units (RSUs) granted under the company’s 2019 Equity Incentive Compensation Plan.
The number of RSUs issued each month will be determined by dividing 90% of his monthly base salary by the fair market value of Edesa’s common shares at each month end. The remaining 10% of his salary will continue to be paid in cash to meet local labor law and withholding requirements. Previously, Dr. Nijhawan received 50% of his base salary as RSUs, so this change further aligns his compensation with the company’s share performance.
Edesa Biotech reported fiscal second quarter 2026 results with a net loss of $4.2 million, or $0.49 per share, for the three months ended March 31, 2026, compared with a net loss of $1.6 million, or $0.30 per share, a year earlier.
Total operating expenses rose to $4.3 million from $1.6 million, driven mainly by higher research and development spending for EB06 vitiligo trial preparations and regulatory and manufacturing work for paridiprubart, along with increased salaries and professional fees.
For the six-month period, the company recorded a net loss of $6.5 million, or $0.78 per share, versus $3.2 million, or $0.74 per share, in the prior-year period. Edesa ended March 31, 2026 with cash and cash equivalents of $10.0 million and working capital of $8.2 million, while advancing preparations for a Phase 2 EB06 vitiligo study and reporting additional positive Phase 3 data for paridiprubart in Acute Respiratory Distress Syndrome.
Edesa Biotech reported additional positive Phase 3 results for its anti-TLR4 antibody paridiprubart in a 278-patient study. Across the full population, paridiprubart cut adjusted 28-day mortality to 24% versus 33% on placebo, a 27% relative risk reduction with strong statistical significance (p<0.001).
In a milder, 174-patient non-IMV subgroup, paridiprubart plus standard of care reduced adjusted 28-day mortality to 15% from 23%, a 35% relative risk reduction (p<0.005). Patients on paridiprubart also showed higher rates of clinical improvement by Day 28, and safety, adverse events and discontinuations were low and similar to placebo.
More than 400 patients have now received paridiprubart. Based partly on these results, Edesa has filed U.S. provisional patents covering use of paridiprubart in sepsis, acute kidney injury and pneumonia, adding to core composition-of-matter patents that extend into the 2030s. The drug is also being tested in a separate, government-funded ARDS study with enrollment of about 200 subjects for the company cohort.
Edesa Biotech, Inc. reported fiscal first quarter 2026 results and highlighted progress in its dermatology and respiratory drug programs. The company is manufacturing EB06, an anti-CXCL10 antibody, and placebo for a planned Phase 2 vitiligo study, with recruitment anticipated midyear 2026, subject to regulatory approvals. Edesa is also analyzing subgroup data and preparing conference presentations following positive Phase 3 results for paridiprubart in Acute Respiratory Distress Syndrome.
Total operating expenses rose to $2.3 million from $1.9 million a year earlier, driven by higher manufacturing-related R&D and increased noncash share-based compensation. Research and development expenses were $1.1 million, while general and administrative expenses were $1.2 million. Total other income declined to $0.1 million from $0.3 million due mainly to lower Canadian government reimbursement funding.
Edesa reported a net loss of $2.2 million, or $0.28 per share, for the quarter ended December 31, 2025, compared with a net loss of $1.6 million, or $0.48 per share, in the prior-year quarter. Cash and cash equivalents were $12.1 million and working capital was $12.0 million at December 31, 2025, supported by $3.4 million in net cash provided by financing activities during the quarter.
Edesa Biotech, Inc. reported that on December 12, 2025 it filed a prospectus supplement to increase to $2,262,508 the maximum aggregate amount of common shares that may be issued under its at-the-market offering agreement with H.C. Wainwright & Co.
The company disclosed that it has previously sold an aggregate of $3,718,324.61 of common shares under a prior prospectus supplement and $837,134 under a 2024 prospectus supplement for the same registration statement. The report also notes that Fasken Martineau DuMoulin LLP provided a legal opinion on the validity of the shares covered and clarifies that this disclosure does not itself constitute an offer to sell these securities.
Edesa Biotech, Inc. filed a current report to disclose that on December 12, 2025 it issued a press release announcing its financial results for the fiscal year ended September 30, 2025. The press release is included as Exhibit 99.1 and is furnished, rather than filed, so it is not automatically subject to certain Exchange Act liabilities or incorporated into other SEC reports unless specifically referenced.
Edesa Biotech (EDSA) reported positive Phase 3 results for paridiprubart (EB05) in ARDS, stating the study met primary and secondary endpoints with statistical significance. In the intention-to-treat population (n=104), 28-day mortality was 39% with paridiprubart plus standard of care versus 52% with placebo, an absolute survival improvement of 13% and a 25% relative risk reduction (p<0.001). A survival benefit persisted at 60 days: 46% vs 59%, a 13% absolute improvement and 22% relative risk reduction (p=0.003).
The company also reported fewer patients required invasive mechanical ventilation, with a 41% higher relative rate of clinical improvement at Day 28. In a safety population of more than 275 subjects across Phase 2/3, EB05 was generally well-tolerated. Patients were enrolled at 38 hospitals in the U.S., Canada and Colombia. The program is supported by the U.S. government’s “Just Breathe” study and Canada’s Strategic Innovation Fund. Enrollment was discontinued early for business reasons, and efficacy analyses used multivariate logistic regression with prespecified adjustments.
Edesa Biotech, Inc. has amended its multi-year contribution agreement with the Government of Canada covering up to CAD $23 million in partially repayable funding for its experimental ARDS drug EB05 (paridiprubart). The amendment shifts the clinical focus from Covid-19–induced Acute Respiratory Distress Syndrome to general ARDS and aligns with participation in a fully funded U.S. government platform study of host-directed therapeutics that includes EB05. The project completion date is extended to December 31, 2028, and the agreement’s expiration moves to the later of December 31, 2045 or the date of last repayment, unless terminated earlier. The repayment schedule is also revised so that the first annual repayment would be due in 2032, and only if the company earns gross revenue, while other terms of the agreement remain in effect.
Edesa Biotech, Inc. filed an 8-K to report that it has filed a new prospectus supplement supporting its at-the-market offering program for the offer and sale of up to $4,006,544 of common shares through H.C. Wainwright & Co. as sales agent. This program operates under an existing At the Market Offering Agreement originally dated October 4, 2024.
The company has previously sold an aggregate of $837,134 of common shares under that agreement and an earlier prospectus supplement tied to a prior Form S-3 registration. The new prospectus supplement and base prospectus form part of a shelf registration statement on Form S-3 that was declared effective by the SEC on September 9, 2025, and a related legal opinion on the validity of the common shares is filed as an exhibit.
Edesa Biotech announced its financial results for the three- and nine-month periods ended June 30, 2025 via a press release that is attached to this Form 8-K as Exhibit 99.1. The filing expressly states the Earnings Release is furnished and shall not be deemed "filed" under the Exchange Act, so it is not subject to Section 18 liabilities and is not incorporated by reference in other filings unless specifically cited. This 8-K itself does not include financial figures or operational details.